Rotavirus vaccination in Europe: drivers and barriers

N Parez, C Giaquinto, C Du Roure… - The Lancet infectious …, 2014 - thelancet.com
Rotavirus gastroenteritis is a vaccine-preventable disease that confers a high medical and
economic burden in more developed countries and can be fatal in less developed countries …

Reduced-Antigen, Combined Diphtheria, Tetanus and Acellular Pertussis Vaccine, Adsorbed (Boostrix®) A Review of its Properties and Use as a Single-Dose Booster …

PL McCormack - Drugs, 2012 - Springer
Reduced-antigen, combined diphtheria, tetanus and three-component acellular pertussis
vaccine (Tdap; Boostrix®) is indicated for booster vaccination against diphtheria, tetanus …

Reduced incidence of invasive pneumococcal disease after introduction of the 13-valent conjugate vaccine in Navarre, Spain, 2001–2013

M Guevara, C Ezpeleta, A Gil-Setas, L Torroba… - Vaccine, 2014 - Elsevier
Pneumococcal conjugate vaccines (PCVs) were licensed for use in children and became
available for private purchase in Spain in 2001 (PCV7), 2009 (PCV10) and 2010 (PCV13) …

[HTML][HTML] Failures of 13-valent conjugated pneumococcal vaccine in age-appropriately vaccinated children 2–59 months of age, Spain

S Hernández, F Moraga-Llop, A Díaz… - Emerging Infectious …, 2020 - ncbi.nlm.nih.gov
Vaccination with the 13-valent conjugated pneumococcal disease (PCV13) has reduced
invasive pneumococcal disease (IPD), but there have been reports of vaccine failures. We …

[HTML][HTML] Direct, indirect and total effects of 13-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in children in Navarra, Spain, 2001 to …

M Guevara, A Barricarte, L Torroba… - …, 2016 - eurosurveillance.org
We estimated the direct, indirect and total effects of the 13-valent pneumococcal conjugate
vaccine (PCV13) on invasive pneumococcal disease (IPD) in children. A population-based …

Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV …

F Martinón-Torres, F Boisnard, S Thomas, C Sadorge… - Vaccine, 2017 - Elsevier
Abstract DTaP5-IPV-HB-Hib vaccine is a fully-liquid, combination hexavalent vaccine. This
phase III, open-label, multicentre study conducted in Spain, evaluated the immune response …

[HTML][HTML] 2009 H1N1: risk factors for hospitalization in a matched case-control study

C Launes, JJ García-García, A Martínez-Planas… - European journal of …, 2012 - Springer
In order to compare sociodemographical data and preexisting risk medical conditions in
patients requiring hospital admission for 2009 pandemic influenza A (H1N1) virus infection …

Availability of pneumococcal vaccination programmes in Europe. An overview of funding mechanisms

R Niżankowski, M Koperny, A Kargul… - Journal of Health Policy …, 2013 - yadda.icm.edu.pl
Increasing antibiotic resistance is a global problem. Vaccinations is one of the best solution
to reduce the burden of infectious diseases. Despite universal access to antibiotics …

Epidemiological, Clinical, and Microbiological Characteristics of Serotype-3 Streptoccocus pneumoniae Infection after a Partial Introduction of the 13-Valent …

A Sole-Ribalta, MF de Sevilla… - Journal of Pediatric …, 2020 - thieme-connect.com
Objective After the introduction of 13-valent pneumococcal conjugate vaccine (PCV13), a
decrease of serotype-3 invasive pneumococcal disease (IPD) has not been homogenously …

Estudio observacional de las hospitalizaciones por rotavirus durante el período 2008-2013 en un área de salud

JLP Rojo, AMH Pérez, MPR Pérez, MTS Jiménez… - Vacunas, 2015 - Elsevier
Objetivos Conocer la carga de enfermedad asociada a gastroenteritis aguda (GEA) por
rotavirus en la población infantil (menores de 5 años) de la provincia de Salamanca …